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Abstract 
Non-tuberculous mycobacterial skin infections have an increasing incidence. In 
immunocompetent patients, they usually follow local trauma. We present a case of 
cutaneous Mycobacterium abscessus infection following mesotherapy. The lesions were 
successfully treated with a combination of clarithromycin, ciprofloxacin, and doxycycline. 
Atypical mycobacterial infection should be suspected in patients who develop late-onset 
skin and soft tissue infection after cutaneous injury, injection, and surgical intervention, 
particularly if they do not respond to conventional antibiotic treatment. 
Introduction 
Skin and soft tissue infections caused by non-tuberculous mycobacteria have been 
increasingly described as a complication associated with many procedures, including 
liposuction, illicit soft tissue augmentation, acupuncture, and contamination from 
medical instruments during surgery [1–5]. Mycobacterium abscessus is a rapid-growing 
atypical mycobacterium that has been reported to cause a variety of cutaneous infections. 
Herein, we report a case of cutaneous M. abscessus infection associated with mesotherapy 
injection. 
Case Report 
A previously healthy 44-year-old woman presented with a 3-week history of tender erythematous 
nodules on her face. The lesions had developed 2 weeks after mesotherapy injection for facial 
rejuvenation, using an unknown substance administered by an uncertified aesthetician. She had no 
fever or other systemic symptoms. Her friends who underwent mesotherapy administered by the same 
practitioner developed similar lesions. The lesions did not improve after a 2-week course of oral  
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cephalexin. Physical examination revealed multiple, discrete, tender erythematous nodules and plaques 
with minimal serosanguinous discharge on both cheeks (fig. 1) and on the forehead (fig. 2). There was 
no lymphadenopathy. The results of the rest of the examination were normal. A skin biopsy specimen 
obtained from a nodule on the right cheek revealed dense inflammation predominantly consisting of 
neutrophils, histiocytes and multinucleated giant cells in the superficial and deep dermis (fig. 3). Gram 
staining, fungal and acid-fast bacilli stains were negative. Tissue culture was positive for M. abscessus, 
sensitive to clarithromycin, ciprofloxacin, doxycycline, cefoxitin, and amikacin. Bacterial and fungal 
cultures were negative. The patient was treated with a combination of clarithromycin 500 mg twice 
daily, doxycycline 100 mg twice daily, and ciprofloxacin 500 mg twice daily according to the bacterial 
sensitivity testing. The lesions started to improve 2 weeks after initiation of the therapy. The patient 
completed 6 months of treatment, which resulted in complete resolution of the lesions with minimal 
atrophic hyperpigmented scars. There was no recurrence at the 3-month follow-up. 
Discussion 
Mesotherapy was first introduced in France in 1952, consisting of an injection of 
highly diluted drugs and different substances into the dermis and subcutaneous tissue. It 
causes both the chemical and physical stimulation of cutaneous mesoderm. Direct 
injection in involved sites allows lower dosages of drugs to be used. All intravenously 
injectable drugs may be used, except oily and alcoholic solvents. This technique was 
originally developed to treat localized pain, vascular and lymphatic disorders, but its use 
in aesthetic medicine has increased in recent years [5]. 
M. abscessus belongs to the group of rapidly growing non-tuberculous mycobacteria 
which is characterized by a rapid growth rate (within 7 days) on the culture. The 
organism is ubiquitously present in soil, decaying vegetation, and water (e.g., natural 
water, sewage water, drinking water tanks, and tap water). M. abscessus causes a wide 
range of clinical diseases including skin and soft-tissue infection, keratitis, osteomyelitis, 
pulmonary infection, and disseminated infection. In skin and soft-tissue infection, it 
usually follows penetrating trauma and typically occurs in immunocompetent individuals 
[6]. There are several reports of outbreaks of M. abscessus infections caused by non-sterile 
techniques or contaminated materials, following surgery, liposuction, foreign body 
implantation, mesotherapy, acupuncture, and soft tissue augmentation [1–5]. 
The clinical presentations of cutaneous M. abscessus infection ranges from 
asymptomatic to tender erythematous violaceous nodules and plaques, cellulitis, 
abscesses, ulcer, and draining sinus with serosanguinous discharge [7]. The lesions may 
be solitary or multiple, and localized lymphadenopathy is occasionally seen. The onset is 
varied from a few weeks to months after exposure [8]. 
Approximately 10–20% of localized cutaneous M. abscessus infections in 
immunocompetent patients resolve spontaneously without treatment in an average of 8 
months [9]. Currently, there is no standard guideline for the treatment of cutaneous M. 
abscessus infection. Multiple modalities including surgery, draining of abscesses, removal 
of necrotic tissue, foreign body removal, and an extended course of antibiotics are 
recommended. The in vitro sensitivity helps guiding antimicrobial therapy. However, the 
in vivo efficacy against the mycobacteria is not completely reflected by in vitro sensitivity 
alone, but also depends on the function of local and general host defenses against the 
infection. M. abscessus is usually susceptible to clarithromycin, amikacin, linezolid, 
tigecycline and variably susceptible to cefoxitin and imipenem (table 1). Clarithromycin 
is generally the recommended drug of choice. It should be given in a combination with  
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other antibiotics for 4–6 months. Monotherapy is not recommended in treating M. 
abscessus infection because of the potential for emergence of antibiotic resistance, as has 
been reported with other mycobacteria, such as Mycobacterium chelonae [10]. 
In conclusion, we report a case of cutaneous M. abscessus infection associated with 
mesotherapy. This case emphasizes the importance of adequate sterile measures in all 
medical procedures and stresses the need to suspect the possibility of an atypical 
mycobacterium infection in patients who develop late-onset skin and soft tissue infection 
after cutaneous injury, injections, and surgical interventions, particularly if they do not 
respond to conventional antibiotic treatment. 
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Table 1. Antimycobacterial drugs, typical sensitivity pattern, and recommended dose for M. abscessus 
infection [6] 
Drugs Typical 
sensitivity 
pattern 
Dosage* and route 
Clarithromycin S  00.500–1,000 mg/day PO 
Azithromycin S .00500–1,000 mg/day PO 
Amikacin S  .0<800–1,000 mg/day IV, IM 
Linezolid S  01,200 mg/day PO 
Tigecycline S  00.100 mg/day IV 
Cefoxitin V  12,000  mg/day  IV 
Imipenem V  .00025 mg/kg/day IV 
Ciprofloxacin R 01,000 mg/day PO 
Sulfamethoxazole   R  03,000 mg/day PO 
Doxycycline R  00.200 mg/day PO 
* Dosage in adult patients with normal renal function. S = sensitive; 
V = variable; R = resistant; PO = per os; IV = intravenous; IM = 
intramuscular. 
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Fig. 1. Erythematous nodules and plaques on the right cheek. 
 
 
 
Fig. 2. Erythematous nodules and plaques on the forehead. 
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Fig. 3. Hematoxylin and eosin-stained slide, ×400. A dense inflammatory infiltrate composed of 
neutrophils and histiocytes in the dermis. 
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